SRP-1005 (ARO-HTT)
Huntington's Disease
Phase 1Active
Key Facts
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology through their Targeted RNAi Molecule (TRiM™) platform to develop therapeutics that silence genes causing disease. With over a decade of experience in RNAi-based therapies, the company has advanced multiple programs across cardiometabolic, liver, and pulmonary diseases. Their lead asset Plozasiran has achieved commercial approval for FCS and is advancing in Phase 3 trials for severe hypertriglyceridemia, demonstrating the platform's potential to address significant unmet medical needs.
View full company profileTherapeutic Areas
Other Huntington's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| PTC518 | PTC Therapeutics | Phase 2 |
| Undisclosed HD Program(s) | WaVe Life Sciences | Preclinical |
| AMT-130 | uniQure | Phase 1/2 |
| Undisclosed Program | Sangamo Therapeutics | Preclinical |
| Pepinemab (VX15/2503) | Vaccinex | Phase 2 |